Status: Not yet recruiting
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Henlius BiotechUpdated: Apr 16, 2026
Eligibility criteria
Voluntarily signed written informed consent and willing to comply with study pro... [+3]
Presence of histological types other than adenocarcinoma in mCRPC; or neuroendoc... [+14]